SCHOFIELD, Wis., April 9, 2014 /PRNewswire/ -- PuraMed
BioScience®, Inc. (OTCBB: PMBS), a researcher, developer, and
marketer of over-the-counter (OTC) medicinal and healthcare
products, announced today that the company is moving forward with
the development of their first cannabinoid-based formulation that
targets the mental health market by focusing on anxiety and
depression.
"We believe that with the technologies we have available,
PuraMed can utilize hemp-derived compounds to build safer, more
effective, and faster-acting treatments for a number of mental
health conditions," said Russ
Mitchell, CEO of PuraMed BioScience.
In 2012, mental health was the second largest US drug class for
spending. In 2011, anti-psychotics and antidepressants accounted
for $29.2 billion in US sales, with
over 264 million prescriptions written for antidepressant
medication.
However, studies show that 63 percent of people who take
antidepressants experience at least one side effect and 30 to 45
percent of people fail to respond to antidepressant treatments.
"PuraMed's long history of building clinically effective herbal
medicines truly sets us apart from the majority of other businesses
entering the cannabis market," said Mitchell. "We believe we can be
a leader in the development of a new generation of natural
medicines that incorporate cannabinoids, which can deliver a
superior level of efficacy without the severe side effects
associated with current prescription drugs.
"We looked at the mental health aspect of development due to our
migraine initiative with veterans who are also suffering with the
effects of Post Traumatic Stress Disorder (PTSD)," said Mitchell.
"Most common treatments for PTSD preclude use of commonly
prescribed migraine treatments. It's a major problem for our
active-duty military as well as our veterans. Movement into
development of a mental health formulation aligns with our efforts
to provide our service men and women with safer and more effective
options which can enhance their quality of life."
Due to the lack of new research on new antidepressant
medications and anxiolytics, we believe there is a strong need for
advancement in this category. The process of formulation and
prototype development is underway.
About PuraMed BioScience, Inc.
PuraMed BioScience
engages in the research, development, and marketing of
non-prescription medicinal and healthcare products. In addition to
LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for
tension-type headaches and LipiGesic PM, which provides a remedy
for insomnia and other sleep disorders.
Forward-Looking Statements
This news release contains forward-looking statements regarding
PuraMed BioScience, Inc., and its future business plans, which
statements involve known and unknown risks and uncertainties. Such
risks and uncertainties may cause actual results and future
achievements of PuraMed BioScience to be materially different from
those implied by these forward-looking statements. PuraMed
BioScience has and undertakes no obligation to provide public
updates and revisions to these forward-looking statements to
reflect any changes in its expectations of future events.
Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and
CEO
715-359-6373
rmitchell@PuramedBioScience.com
www.PuramedBioScience.com
SOURCE PuraMed BioScience, Inc.